Welcome to LookChem.com Sign In|Join Free
The company logo of Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Free supplier Enterprise Certification

Free
supplier
8th
years

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Business Type:Lab/Research institutions

Audited Supplier

Main Products:
Year Established:
2017
Home>>Products>>OICR-9429

Products Categories

Product Certification&
Enterprise Certification

More Detail

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Country: China (Mainland)

Business Type:Lab/Research institutions

OICR-9429

CAS NO.1801787-56-3

  • Min.Order: 10 Milligram
  • Payment Terms:
Contact Supplier

Product Details

Keywords

  • OICR-9429
  • OICR 9429
  • OICR9429

Quick Details

  • ProName: OICR-9429
  • CasNo: 1801787-56-3
  • Molecular Formula: C29H32F3N5O3
  • Application: For laboratory use only- not intended ...
  • ProductionCapacity: 1 Kilogram/Month
  • Purity: ≥98%
  • Storage: room temperature
  • Transportation: For laboratory use only- not intended ...
  • LimitNum: 10 Milligram

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

 

 

 

Details

OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction with IC50 of 5 uM. inhibit proliferation and induce differentiation . target: Wdr5 IC 50: 5 uM In vitro: OICR-9429 inhibit proliferation and induce differentiation in p30-expressing human AML cells. OICR-9429 cause a significant decrease in viability in the majority of patient cells with mutations in the N-terminal part of the CEBPA gene. OICR-9429 displays exquisite cellular selectivity and specificity in disrupting critical protein-protein interactions between WDR5. [1] reduce the viability of primary human AML cells with N-terminal C/EBPα mutations by about 50% (mean value, n = 8) at 5 μM [2] In vivo:The reference for OICR-9429 to mice (female NOD-SCID) is 3 mg/kg.

Hot Product